Charles River Laboratories Intl. Inc vs Fidelity National Information Servcs Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Fidelity National Information Servcs Inc for 88 Days on average.
| CRL | FIS | |
|---|---|---|
Market Cap | $14.23B | $17.71B |
Volume | 1,176,885 | 9,047,825 |
Sector | Health | Technology |
52-Week High | $310.77 | $68.57 |
52-Week Low | $149.93 | $32.44 |
Typical Hold Time | 33 Days | 88 Days |
Enterprise Value | $17.06B | $38.22B |
Dividend Yield | — | 5.13% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while profitability has improved significantly with net income margin reaching 27.65% in 2026 projections. Recent business developments include multiple core banking platform wins and new product launches, positioning the company for growth in financial technology modernization.
FIS presents a compelling value opportunity with strong analyst support (56.76% buy ratings) and a $47.15 consensus price target representing 37% upside. However, investors face risks from the company's elevated debt levels and inconsistent cash flow generation. The technical bearish signal and recent price weakness suggest potential near-term volatility despite fundamental improvements.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →